Celldex Therapeutics Inc (CLDX)

[TFMG]

$CLDX PRE MARKET MOVER ON POSITIVE DATA

********CLDX PRESENTED ENCOURAGING DADA AT THE ASCO ANNUAL MEETING ON JUNE 1st, WHICH HAS GOT THE ATTENTION OF INVESTORS PREMARKET, WITH A 15% POP, SPECULATIVE BUT POSSIBLY VERY REWARDING************

“We have observed intriguing clinical activity across a number of patients with similar gene mutation patterns in a disease that has extremely limited treatment options and a particularly poor prognosis,” said Dr . Bauman. “While the data are early, they are provocative and suggest the potential for a biomarker enrichment strategy that could change the standard of care for these patients. I look forward to the opportunity to obtain additional data on CDX-3379 in biomarker selected patient populations.”


AVERAGE ANALYSTS PRICE TARGET $19
AVERAGE ANALYSTS RECOMMENDATION BUY

CELLDEX THERAPEUTICS INC.
Celldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.